Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®

- CMS streamlines reimbursement for DAXXIFY with assignment of permanent J-code -


- Peer-reviewed publication of DAXXIFY pivotal data in therapeutics reinforces the products long duration of effect...

Related Keywords

United States ,China ,American ,Cynthial Comella ,Markj Foley , ,Dystonia Medical Research Foundation ,Drug Administration ,Securities Exchange ,Exchange Commission ,Revance Therapeutics Inc ,Peptide Exchange Technology ,Linkedin ,Viatris Inc ,American Academy Of Neurology ,Us Centers For Medicare Medicaid Services ,Revance Therapeutics ,Medicaid Services ,American Academy ,Chief Executive ,Atul Patel ,Boxed Warning ,Distant Spread ,Specific Populations ,Prescribing Information ,Shanghai Fosun Pharmaceutical ,Resilient Hyaluronic Acid ,Private Securities Litigation Reform Act ,Securities Act ,Securities Exchange Act ,Markets ,